welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Tucson pharmaceutical company sells exclusive option for cancer drug in deal worth up to $190 million
Sucampo unveiled Monday its agreement with Tuscon, Arizona-based Cancer Prevention Pharmaceuticals Inc. for the option to acquire an exclusive license to commercialize for a drug candidate in Phase III clinical trials. The therapy is aimed at treating a genetic condition called Familial Adenomatous Polyposis, or FAP, which can develop into colon cancer if it’s left untreated.
expertly curated content related to this topic
-
Peter G. Deveaux, MDPeter G. Deveaux, MD is an assistant pro...
-
@TravisHBrayA research chemist in my previous life, ...
-
Susan G. Coe, MDDr. Coe is a member of several...
-
Arnold J. Markowitz, MDArnold J. Markowitz is a board-certified...
-
UW Health – University of Wisconsin Hospitals and ClinicsUW Health is an academic health system a...
-
Jaime L. Bohl, MDDr. Bohl is an authority in the area of ...
-
Infographic: How to Read a Scientific PaperMuch of a scientist’s work involves re...